AbbVie's Q2 Oncology Revenue Expected to Decline Slightly
AbbVie's (ABBV) oncology franchise is expected to report a slight revenue decline in Q2 2025, as weakness in Imbruvica sales offsets growth from Venclexta and newer cancer drugs.
According to a Zacks report, AbbVie's (ABBV) oncology revenue is expected to edge lower in Q2 2025. Despite growth from Venclexta and newer therapies, declining Imbruvica sales remain a drag.
Key Financial Metrics
AbbVie has not yet reported Q2 results, but expectations include:
| Metric | Expectation |
|---|---|
| Oncology Revenue | Slight decline QoQ |
| Imbruvica | Continued decline |
| Venclexta | Moderate growth |
Key Takeaways
- Imbruvica faces competition from newer therapies.
- Venclexta growth supported by new approvals.
- Newer therapies contribute modestly.
Guidance
No official guidance provided; analysts expect continued pressure on oncology revenue in H2.
Impact on Stock
ABBV stock may face mild short-term pressure, but investors await actual Q2 results.
What This Means for Investors
Investors should monitor AbbVie's Q2 results closely. The oncology segment is a key revenue driver, but portfolio diversification may mitigate Imbruvica's weakness.
Frequently Asked Questions
Found this useful? Share it